CompletedPhase 2NCT02194231
ATREUS - Phase II Study on the Activity of Trabectedin in Patients With Malignant Pleural Mesothelioma (MPM)
Studying Pleural mesothelioma
Last synced from ClinicalTrials.gov
ℹ
Clinical trial records are synced from ClinicalTrials.gov through automated extraction.
Report missing dataKey facts
- Sponsor
- Mario Negri Institute for Pharmacological Research
- Principal Investigator
- Paolo Bidoli, MDAzienda Ospedaliera San Gerardo di Monza
- Intervention
- Trabectedin(drug)
- Enrollment
- 145 target
- Eligibility
- 18 years · All sexes
- Timeline
- 2013 – 2019
Study locations (8)
- Azienda ospedaliera ss. Antonio e Biagio e Cesare Arrigo, Alessandria, AL, Italy
- Cliniche Humanitas Gavazzeni, Bergamo, BG, Italy
- Azienda Ospedaliera Universitaria Policlinico Sant'Orsola Malpighi, Bologna, Bo, Italy
- P.O. Spedalli Civili, Brescia, BS, Italy
- Azienda Ospedaliera S. Gerardo di Monza, Monza, MB, Italy
- Istituto Clinico Humanitas, Rozzano, MI, Italy
- Istituto Oncologico Veneto - IOV, Padua, PD, Italy
- Azienda Ospedaliro-Universitaria di Parma, Parma, Italy
Collaborators
PharmaMar
Primary source
Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.
Open NCT02194231 on ClinicalTrials.govOther trials for Pleural mesothelioma
Additional recruiting or active studies for the same condition.
- RECRUITINGPHASE1NCT07192900Fast TILs to Treat Metastatic Cancer Patients With Pleural DiseaseDavid Bartlett, MD
- RECRUITINGNANCT07126509Partial Pleurectomy (Surgery) for Unresectable Pleural MesotheliomaUniversity of Chicago
- RECRUITINGPHASE1, PHASE2NCT07121374NEoadjuvant Chemotherapy and Immunotherapy for a Selected Group of Inoperable Pleural Mesothelioma Patients (NECIM): a Feasibility StudyUniversity Hospital, Antwerp
- RECRUITINGPHASE1NCT06885697Anti-Mesothelin TNaive/SCM hYP218 (TNhYP218) CAR T Cells in Participants With Mesothelin-Expressing Solid Tumors Including MesotheliomaNational Cancer Institute (NCI)
- RECRUITINGPHASE2NCT06840834Evaluating Ivonescimab as a Potential Treatment for Pleural Mesothelioma Patients Whose Cancer Has Returned After Previous Immunotherapy and ChemotherapyIntergroupe Francophone de Cancerologie Thoracique
- RECRUITINGPHASE2NCT06875076Multicenter Single-Arm Study of Ivonescimab (AK112) Combined with Chemotherapy in Pretreated Pleural MesotheliomaThe First Hospital of Jilin University
- RECRUITINGPHASE2NCT06790082The Diagnostic Accuracy and Clinical Value of FAPI PET in Pleural MesotheliomaAalborg University Hospital
- RECRUITINGPHASE1NCT06566079Study of ISM6331 in Participants With Advanced/Metastatic Malignant Mesothelioma or Other Solid TumorsInSilico Medicine Hong Kong Limited